New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - levomepromazine hydrochloride 25 mg/ml equivalent to 22.5 mg/ml levomepromazine base;   - solution for injection - 25 mg/ml - active: levomepromazine hydrochloride 25 mg/ml equivalent to 22.5 mg/ml levomepromazine base   excipient: ascorbic acid sodium chloride sodium sulfite water for injection - nozinan is indicated in the management of terminal pain and accompanying restlessness or distress.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - disopyramide 100mg (as base) - capsule - 100 mg - active: disopyramide 100mg (as base) excipient: gelatin indigo carmine iron oxide red magnesium stearate maize starch purified talc starch titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - disopyramide 150mg (as base) - capsule - 150 mg - active: disopyramide 150mg (as base) excipient: gelatin magnesium stearate maize starch purified talc starch titanium dioxide

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - rivastigmine base - transdermal patch - 4.6 mg/day - anticholinesterases

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - rivastigmine base - transdermal patch - 9.5 mg/day - anticholinesterases

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - rivastigmine base - transdermal patch - 4.6 mg/24 hours - anticholinesterases

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - rivastigmine base - transdermal patch - 9.5 mg/24 hours - anticholinesterases

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - rivastigmine base - transdermal patch - 13.3/24 - anticholinesterases

Israel - English - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - film coated tablets - moxifloxacin as hydrochloride 0.4 g - moxifloxacin - moxifloxacin - for the treatment of the following bacterial infections in patients of 18 years and older• respiratory infections : - uncomplicated acute bacterial sinusitis (abs) - acute exacerbations of chronic bronchitis (aecb) megaxin tablets should be used to treat adequately diagnosed abs and aecb only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections or when these have failed to resolve the infection. - community acquired pneumonia, except severe cases. megaxin tablets should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of this infection. • community-acquired spontaneous and wound infections of the skin and skin structure.appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin tablets may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - English - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - film coated tablets - moxifloxacin as hydrochloride 0.4 g - moxifloxacin - moxifloxacin - for the treatment of the following bacterial infections in patients of 18 years and older• respiratory infections : - uncomplicated acute bacterial sinusitis (abs) - acute exacerbations of chronic bronchitis (aecb) megaxin tablets should be used to treat adequately diagnosed abs and aecb only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections or when these have failed to resolve the infection. - community acquired pneumonia, except severe cases. megaxin tablets should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of this infection. • community-acquired spontaneous and wound infections of the skin and skin structure.appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin tablets may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.consideration should be given to official guidance on the appropriate use of antibacterial agents.